Results 241 to 250 of about 125,690 (294)

Hypertrophic cardiomyopathy management: a systematic review of the clinical practice guidelines and recommendations. [PDF]

Eur Heart J Qual Care Clin Outcomes
Sanghvi MM, Dhall E, Anwar A Chahal C, O'Mahony C, Mohiddin SA, Savvatis K, Ricci F, Munroe PB, Petersen SE, Aung N, Khanji MY.   +10 more
europepmc   +1 more source

Minimally Invasive Repair of Left Ventricular Aneurysm After Esophagectomy With Retrosternal Gastric Conduit: A Case Report

Clinical Case Reports, Volume 13, Issue 12, December 2025.
Preoperative CT and 3D reconstruction demonstrating an inferior left ventricular aneurysm in a patient with a retrosternal gastric conduit, highlighting the rationale for choosing a left mini‐thoracotomy approach. ABSTRACT In patients with prior esophagectomy and retrosternal gastric conduit, conventional sternotomy may be hazardous.
Junya Kitaura, Tomokuni Furukawa, Kazuki Maeda   +2 more
wiley   +1 more source

Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy. [PDF]

J Cardiovasc Imaging
Choi YJ, Lakdawala NK.
europepmc   +1 more source

Molecular Genetics of Hypertrophic Cardiomyopathy

, 2005
Ali J. Marian
openalex   +2 more sources

Impact pathway and gene ontology analyses of FOXC2‐correlated genes in melanoma reveal a role for the FOXC2 transcription factor in several oncogenic pathways and processes

Clinical and Translational Discovery, Volume 5, Issue 6, December 2025.
FOXC2‐correlated genes identified from publicly available RNA‐sequencing datasets of independent skin cutaneous melanoma patient cohorts were analysed using various bioinformatic approaches. Our data reveal biologic pathways and processes significantly impacted by FOXC2‐correlated genes and offer novel insights into the oncogenic functions of FOXC2 in ...
Kristian M. Hargadon, Balázs Györffy, James B. Wall   +2 more
wiley   +1 more source

Cardiac myosin inhibitors in hypertrophic cardiomyopathy. [PDF]

J Cardiovasc Imaging
Lim J, Kim HK.
europepmc   +1 more source

Association of Long‐Term Oral β‐Blocker Use With Cardiac Troponin I and B‐Type Natriuretic Peptide in Septic Myocardial Injury: A Retrospective Cohort Study

Health Science Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background and Aims Septic myocardial injury, characterized by elevated levels of cardiac troponin I (cTnI) and B‐type natriuretic peptide (BNP), is associated with increased mortality in sepsis. This study aimed to evaluate whether chronic oral β‐blocker use is associated with reduced cardiac biomarker levels and improved short‐term outcomes.
Zheng Yang, Aihua Jiang, Yunlong Zhu, Kaiqi Cao, Jianbiao Meng, Fang Han, Chun Yang   +6 more
wiley   +1 more source

ROS accelerates the progression of hypertrophic cardiomyopathy. [PDF]

Genes Dis
Cao J, Zhai Y, Li K, Li J, Tian X, Zhang J, Li S, Liu M, Li X, Dong J, Wang X.   +10 more
europepmc   +1 more source

Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM

The Journal of Clinical Pharmacology, Volume 65, Issue 12, Page 1802-1814, December 2025.
Abstract Mavacamten, a cardiac myosin inhibitor, is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, and coadministration with strong CYP3A4 or CYP2C19 inhibitors was contraindicated in patients with obstructive hypertrophic cardiomyopathy (HCM) in the US Prescribing Information. This study assessed the safety and efficacy
Samira Merali, Haden Bunn, Caroline Sychterz, Manting Chiang, Shilpa Puli, Amy J. Sehnert, Bindu Murthy, Joga Gobburu   +7 more
wiley   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +1 more source